Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care

HRSA redrafts 340B rebate pilot program after courts block the original version

After returning to the drawing board, the Health Resources and Services Administration has announced a second iteration of the 340B Rebate Model Pilot Program, after it withdrew the original pilot earlier this year.

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer.

August 07, 2026

Vol.52 No.31

In Brief

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Dana-Farber Cancer Institute’s Department of Pathology, in collaboration with Brigham and Women’s Hospital, has received renewed funding for the Ruth L. Kirschstein NRSA Institutional Research Training Grant from the NCI, providing resources for pathology residents, clinical fellows, and PhD-trained scientists pursuing research careers in cancer pathology.

August 07, 2026

Vol.52 No.31

Cancer History Project

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

If a Mount Rushmore of Epidemiology were to exist, Joseph F. Fraumeni Jr. would be etched into the face of the mountain, former NCI Director Ned Sharpless once told Stephen J. Chanock.

July 31, 2026

Vol.52 No.30

By Sara Willa Ernst

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure.

July 10, 2026

Vol.52 No.27

By Journal of Clinical Oncology

In Brief

Ned Sharpless’s portrait unveiled at FNIH ceremony

Former NCI director Norman “Ned” Sharpless had his portrait unveiled at a ceremony hosted by the Foundation for the National Institutes of Health on the main NIH campus in Bethesda.

July 10, 2026

Vol.52 No.27

Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care

YOU MAY BE INTERESTED IN

HRSA redrafts 340B rebate pilot program after courts block the original version

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

The long life of a clinical trial
How JCO sustains landmark oncology research

Ned Sharpless’s portrait unveiled at FNIH ceremony

Renew today!

Subscriber content

Never miss an issue!

Login

Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care

YOU MAY BE INTERESTED IN

HRSA redrafts 340B rebate pilot program after courts block the original version

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”Chanock and Brawley reflect on their illustrious mentor

The long life of a clinical trialHow JCO sustains landmark oncology research

Ned Sharpless’s portrait unveiled at FNIH ceremony

Never miss an issue!

Login

Joseph F. Fraumeni Jr., inventor of molecular epidemiology, was a “gentle giant” who “bet on the good people”
Chanock and Brawley reflect on their illustrious mentor

The long life of a clinical trial
How JCO sustains landmark oncology research